6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6-month Safety Extension Period
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007684/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Primary Objective:
- To compare the efficacy of insulin glargine new formulation and Lantus in terms of
change in Glycated Hemoglobin A1c (HbA1c) from baseline to endpoint (scheduled Month 6)
in adult participants with type 2 diabetes mellitus
Secondary Objective:
- To compare the efficacy of insulin glargine new formulation and Lantus in terms of
occurrence of nocturnal hypoglycemia
提供机构：
Vivli
创建时间：
2022-02-10
